Xenon Receives BIOTECanada Gold Leaf Award

Tuesday, June 17, 2008 General News J E 4
VANCOUVER, British Columbia, June 17 Xenon PharmaceuticalsInc., a drug discovery and development company, is pleased to announce todaythat it has been awarded the Promising Early Stage Company of the Year Awardby BIOTECanada in the Health category for 2008.

"We are delighted to have received this prestigious award, one ofBIOTECanada's four Gold Leaf Awards presented this year," commented SimonPimstone, Xenon's President and CEO. "This honor is important and made evenmore so by the fact that it represents recognition by our industry peers ofboth our achievements to date and the potential that Xenon offers."

"Xenon has made substantial progress in advancing its pipeline of novelcompounds acting against targets derived from our clinical genetics approach.In the next 12 months we should have multiple products in clinical developmentfor potential blockbuster markets. Our product pipeline is diverse, and weare excited to be advancing our discoveries into clinical opportunities,"Pimstone added.

About Xenon Pharmaceuticals Inc.

Xenon is a privately owned, clinical genetics-based drug discovery anddevelopment company engaged in developing small molecule therapies focusing inpain, lipid modification for treating diabetes/obesity and other diseases, aswell as therapies for treating anemia and diseases of iron overload. Xenonhas partnerships with Novartis Pharma AG, Roche and Takeda PharmaceuticalCompany Ltd. For more information, visit the Company's website at

SOURCE Xenon Pharmaceuticals Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Transgenomic Introduces SURVEYOR(R) Endonuclease A...
IPA Now Supports Affymetrix Exon Arrays and Additi...